Group items matching

in title, tags, annotations or url

The International Congress for the History of Pharmacy is a biennial meeting of historians, pharmacists and other researchers and health professionals from around the world interested in the history of pharmacy and pharmaceuticals. This year's Congress is co-sponsored by AIHP and the International Society for the History of Pharmacy, and is supported by a generous grant from the United States Pharmacopeial Convention (USP). The conference will be held in Washington, DC, at the Capital Hilton, on September 5-8, 2019. The theme of the Congress is "The Pharmacist and Quality Medicines." Four plenary lectures and more than 50 papers will focus on a broad range of topics related to all aspects of history of pharmacy and medicines, including the training and regulation of pharmacists and the social, scientific, technologic, and economic aspects of pharmaceuticals and the pharmaceutical industry. The conference will be of interest to scholars in the history of pharmacy and medicine and related fields. Plenary lectures will be given by noted historians William B. McAllister, Jacalyn Duffin, Michael Flannery, and Lucas Richert. The full conference schedule is available here. The conference website can be found here.

HEALTH OUTCOMES RESEARCH: Outcomes research spans a broad spectrum of issues from studies evaluating the effectiveness of a particular pharmaceutical intervention to the impact of reimbursement policies on the outcomes of care. It also ranges from the development and use of tools to perform patient-based assessments to analyses of the best way to disseminate the results of outcomes research to providers or consumers to encourage behavior change. Outcomes research incorporates a variety of research methods from various disciplines. The application of outcomes research principles in evaluating the design, delivery, and effectiveness of pharmaceuticals includes the following general areas: * Burden of Disease * Comparative Effectiveness Research * Compliance/Adherence * Cost Consequences Analysis * Cost-Benefit Analysis * Cost-Effectiveness Analysis * Cost Utility Analysis * Patient Satisfaction * Patient Preferences * Psychometric Evaluation of Questionnaires (e.g. reliability, validity, etc.)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support screening of target-based pharmaceutical libraries to identify candidate therapeutics against select eukaryotic pathogens and subsequent preclinical development activities.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support screening of target-based pharmaceutical libraries to identify candidate therapeutics against select eukaryotic pathogens and subsequent preclinical development activities.

The Alcohol, Drug, and Tobacco Study Group (ADTSG) of the Society for Medical Anthropology requests submissions for the best graduate student paper in the anthropology of alcohol, drugs, pharmaceuticals, tobacco or similar substances.

NineSigma, representing a multibillion-dollar global beverage manufacturer, seeks a natural agent with an antimicrobial or bacteriostatic activity against molds and yeasts, as well as its derived component. The client ultimately wishes to apply the sought agent to beverage development; however, proposals for an agent that has been proven applicable not only to beverages, but also to food, pharmaceutical products and cosmetics are welcome from a wide range of industries. It is preferable that an agent can exert its effect when used alone; however, the client also seeks proposals for combined use of multiple natural antimicrobial and/or bacteriostatic agents and for a masking technology for an antimicrobial or bacteriostatic agent that is known to adversely affect taste and flavor.

The PhRMA Foundation is accepting applications to its Health Outcomes program. Health Outcomes research spans a broad spectrum of issues related to healthcare delivery, from studies evaluating the effectiveness of a pharmaceutical intervention to the impact of reimbursement policies on outcomes of care. It also ranges from the development and use of tools to perform patient-based assessments to analyses of ways in which results of outcomes research are disseminated to providers or consumers to encourage behavior change. Through the program, one-year grants of up to $100,000 will be awarded to assist individuals beginning an independent research career in health outcomes at the faculty level. Schools of medicine, pharmacy, public health, nursing, and dentistry are eligible to apply. The program is not intended for individuals in postdoctoral training. However, those enrolled in postdoctoral training programs scheduled to conclude by July 1, 2019, and who will hold an academic appointment by that time may apply. Those holding the academic rank of instructor or assistant professor and investigators at the doctoral level with equivalent positions are eligible to apply - provided the proposed research is neither directly nor indirectly subsidized to any significant degree by an extramural support mechanism. All applicants must be a citizen or permanent resident of the United States. For complete program guidelines and application instructions, see the PhRMA Foundation website.

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds through the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point.  Finally, this FOA will support animal studies to prove efficacy if the candidate compound is patentable and has a plausible path to commercialization.  Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA. 

The goal of this program is to support the advancement of regulatory science to facilitate the implementation and the assessment of continuous manufacturing and similar innovative monitoring and control techniques in the pharmaceutical sector. This will be accomplished by making awards to institutions of higher education and nonprofit organizations for the purpose of studying and recommending improvements to the process of continuous manufacturing of drugs and biological products (e.g., monoclonal antibodies and therapeutic enzymes). Examples of activities could include the development or modification of a novel manufacturing process (e.g., design, scale-up, and/or commercial scale), control method, and/or testing technology. Awards made under this FOA may be funded in part by appropriations received under the 21st Century Cures Act, section 3016.

This call is open to all respondents, and we particularly encourage proposals from the private sector and/or entities that have partnerships with the private sector - to ensure a pathway to commercialization at scale. Our first principle is to leverage existing innovation within the food and beverage industry and its suppliers for new applications that can reach low-income consumers, for greatest scale and impact. We also welcome technologies and translational approaches based on knowledge from ancillary fields, e.g., veterinary science, pharmaceuticals, etc.

Pharmaceutical company AmerisourceBergen created the AmerisourceBergen Foundation as a separate not-for-profit charitable organization with the aim of supporting health and education-related causes that enrich the lives of its global community. To accomplish that goal, the foundation provides funding for programs and organizations focused on expanding access to quality healthcare - both human and animal - around the world. In the view of the foundation, the current epidemic of opioid abuse and misuse is a crisis that demands attention, action, and accountability. Understanding the need for expediency, the foundation is inviting grant-funded nonprofit organizations to submit proposals that describe how it can best contribute resources and funding to address opioid abuse and misuse. Grants will be awarded for the most innovative and constructive solutions in one of two key areas of focus: safe disposal and education around prevention. Applicants are strongly encouraged to identify and leverage existing, proven, evidence-based frameworks and strategies, as well as existing tools and materials, but may also propose original and innovative projects. Applications focused on education may address a spectrum of needs, but priority will be given to the effective dissemination of the following topics: provider education about appropriate opioid prescribing; patient education about the risks and effects of prescription opioids, and what to do if they have concerns about addiction; public education, especially aimed at rural communities; training to reduce youth risk factors (such as delinquency) and boost protective factors (such as decision-making skills for problem solving and resisting peer pressure; addiction as a childhood onset condition; preventing teens from initiating problematic opioid use in the first place; and advising parents of teens to lock up prescription opioid medications and dispose of old pills.

NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material.

NIJ's drugs and crime portfolio supports research on law enforcement efforts to deter, investigate, prosecute, and address illegal drug trafficking, markets, and use. This FY2018 solicitation seeks investigator-initiated proposals to conduct applied research on evidence-based tools, protocols, and policies for State, local and tribal jurisdictions. The two drug priorities are: 1) opioid-related criminal investigation, prosecution, drug intelligence, and community surveillance; and 2) illegal marijuana markets and drug-related violent crime. Opioid research proposals should address narcotics law enforcement, forensic science, and/or medicolegal death investigations; and opioids include heroin, fentanyl, diverted pharmaceuticals, synthetic drugs, and analogues.

The FDA Center for Drug Evaluation and Research seeks to support efforts to research, identify key issues, and convene appropriate subject matter experts to help advance regulatory science to promote the increased availability of safe and effective drugs to the public. This effort will inform regulatory science by advancing the scientific discussion of key research topics of interest to both FDA and external stakeholders such as the pharmaceutical industry, healthcare professionals, patients, and academic researchers. FDA seeks support to address research needs identified in the 2018 reauthorization of the Prescription Drug User Fee Act (PDUFA VI) and requirements under the 21st Century Cures Act. The research areas identified in PDUFA and the 21st Century Cures Act represent key scientific priorities identified by FDA, Congress, and stakeholders that, if advanced, will help expedite the development of drugs and improve efforts to assess their safety and effectiveness, thereby increasing the availability of safe and effective drugs to the public.

This Funding Opportunity Announcement (FOA) invites an application from the current awardee institution of the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal (AMP T2D KP). The AMP T2D program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time FOA to provide funds to the AMP T2D KP to continue the development of the web portal and underlying, curated knowledge base; as well as to become the flagship resource encompassing the myriad types of data and information that provides an understanding of the biological heterogeneity in patients with T2D and its complications. In its next five-year period, the AMP T2D KP will be expected to expand the KPs data sets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base. To support the conduct of these studies, the AMP T2D KP will coordinate, support, and work with companion Functional Genomic Project awardees (RFA-DK-19-012) to form a Consortium. The AMP T2D KP will also oversee an opportunity pool of funds to solicit collaborative projects to accomplish the objectives of the Consortium.

This cooperative agreement funding opportunity is a continuation towards the development of the Integrated Food Safety System (IFSS) National Curriculum Standard (NCS) for the various jobs within the human food, animal food, and laboratory regulatory programs (retail food, human manufactured food, animal food, produce, milk, lab, and shellfish) with the ability to expand into other program areas as directed (pharmaceuticals, medical devices, radiological health, imports, bioresearch monitoring, tobacco, leadership and management or other training programs OTED, is or becomes responsible for); continuation of conducting course deliveries, researching and assessing stakeholder training needs; researching the effectiveness of current training models; development of a curriculum tracking database; and the design, development and/or evaluation of new or existing web and classroom courses, materials, and job aids for classroom or field training as directed.

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include: Pediatric Oncology -Innovations in pediatric oncology port technologies -Drugs that target pediatric-specific driver genes -Bedside, rapid tumor genetic testing Pediatric Surgical Care -Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants -Innovative treatment options for adolescent idiopathic scoliosis -Surgical robotics to treat pediatric patients Influenza -Pediatric-focused innovations in influenza -Novel solutions for influenza vaccine delivery -Influenza pre-exposure including antivirals prophylaxis formulation Applications will be accepted across: -Pharmaceuticals -Medical devices -Consumer products -Global public health -Health technologies -Cross-sector initiatives (an integration of one or more areas of focus mentioned above) Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria: -Potential impact -Uniqueness of solution & level of competition in the current market -Quality & feasibility of the technology -Team credibility & capabilities -Plans for utilizing JLABS @ Washington, DC

The Ohio Opioid Abuse, Prevention and Treatment Technology Initiative is to accelerate the development and commercialization of promising new products (or adaptations or modifications) in the categories of medical devices, diagnostics, pharmaceuticals, and health technology.  They should meaningfully address one or more issues associated with the drug crisis driven by use, misuse, abuse and the addictive potential of opioids. Specifically, projects must contribute to near term tangible solutions associated with addiction prevention, treatment and overdose intervention. Technology and products that enable safe and effective treatment of acute and chronic pain without the use of opioids are encouraged. 

ENTELLIGENCE, in partnership with Actelion Pharmaceuticals US, supports basic science, translational, and clinical research in the field of cardiopulmonary medicine. The program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research in pulmonary hypertension. To that end, ENTELLIGENCE is accepting applications for its thirteenth annual Young Investigator grant program. Established in 2005, the program provides opportunities for promising young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, clinical, or translational) in the area of pulmonary hypertension specifically related to expanding knowledge of pulmonary vascular pathobiology pathways. In 2018, the program will award a one-year grant of up to $100,000 to fund a mentored project.

The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process. Both the project period and budget of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding. Project aims can range from the development of a new molecular entity to the expansion of an existing medication's clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.